Photo: poba/Getty Images

照片：波巴/盖蒂图片社

A consortium of research institutes in South Korea has been formed to promote the utilisation of AI and national supercomputers in discovering novel drugs for treating lung cancer.

韩国成立了一个研究机构联盟，以促进人工智能和国家超级计算机在发现治疗肺癌的新药方面的应用。

According to a press statement, the following organisations will collaborate to develop and test AI for identifying novel drug candidates and predicting its efficacy:

根据一份新闻声明，以下组织将合作开发和测试人工智能，以识别新型候选药物并预测其疗效：

DAAN Cancer Research Institute under Yonsei University's College of Medicine

延世大学医学院大安癌症研究所

Daegu Gyeongbuk Institute of Science and Technology (DGIST)

大邱庆北科学技术研究所（DGIST）

Korea Research Institute of Chemical Technology (KRICT)

韩国化学技术研究所（KRICT）

Korea Advanced Institute of Science and Technology (KAIST)

韩国高级科学技术学院（KAIST）

Biotechnology company J INTS BIO

生物技术公司J INTS BIO

WHAT IT'S ABOUT

是关于什么的

The consortium's research will be done in four phases: First, the collection of lung cancer tissue and genomic samples, to be led by Yonsei University's DAAN Cancer Research; second, the simulation and analysis of protein-drug interactions using supercomputers and AI at the DGIST Core Protein Resources Center; third, the synthesis of AI-identified drug candidates through pharmacological and toxicological assessments at KRICT; and lastly, the validation through clinical trials of AI's predictive capability and accuracy.

该联盟的研究将分四个阶段进行：首先，收集肺癌组织和基因组样本，由延世大学的大安癌症研究所领导；其次，在DGIST核心蛋白质资源中心使用超级计算机和AI模拟和分析蛋白质-药物相互作用；第三，AI的合成通过KRICT的药理学和毒理学评估确定了候选药物；最后，通过临床试验验证AI的预测能力和准确性。

.

.

Besides overseeing the entire research, J INTS BIO will also lead the development of patient-specific treatment protocols for administering their potential anti-lung cancer drug.

。

The consortium also aims to build 'extensive cancer data infrastructures' that will underpin ongoing research. They target to present the initial findings of their research by the first half of next year.

该联盟还旨在建立“广泛的癌症数据基础设施”，以支持正在进行的研究。他们的目标是在明年上半年公布他们研究的初步结果。

WHY IT MATTERS

为什么它很重要

This collaboration emphasises the use of AI and supercomputers to complement measures addressing persistent challenges in anti-cancer drug discovery and development, particularly low effectiveness and high toxicity.

这种合作强调使用人工智能和超级计算机来补充应对抗癌药物发现和开发中持续挑战的措施，特别是低效性和高毒性。

The consortium underscored AI's value in drug discovery by helping hasten the process while helping minimise clinical trial failure rates.

该财团强调了人工智能在药物发现中的价值，它有助于加速这一过程，同时有助于最大限度地降低临床试验失败率。

'AI's capacity to process immense biological datasets and apply machine learning for patient-specific predictions can drastically reduce clinical trial failure rates and accelerate the entire drug discovery process,' said KAIST professor Joung Ho Kim.

KAIST教授Joung Ho Kim说：“人工智能处理大量生物数据集并将机器学习应用于患者特定预测的能力可以大大降低临床试验失败率并加速整个药物发现过程。”。

Utilising AI and supercomputers can also enable the 'ultra-precise' analysis of patient tissues and genetic profiles, facilitating the design of personalised treatments, said Byoung Chul Cho, a professor from Yonsei's Severance Hospital. He was also part of the research team that developed a branded oral non-small cell lung cancer drug. .

延世遣散医院（Yonsei'sSeverance Hospital）教授Byoung Chul Cho表示，利用人工智能和超级计算机还可以对患者组织和基因图谱进行“超精确”分析，从而促进个性化治疗的设计。他也是开发品牌口服非小细胞肺癌药物的研究团队的一员。。

THE LARGER TREND

更大的趋势

Last year, the South Korean government started allowing researchers across the country to access public and clinical data on cancer through the K-CURE service. In August, access to more cancer data types on K-CURE was expanded.

去年，韩国政府开始允许全国各地的研究人员通过K-CURE服务获取有关癌症的公共和临床数据。。

Meanwhile, the Korean government also recently announced that it intends to develop a system to rapidly develop and verify new drug targets for non-immune solid cancers as part of initiatives under the Korean Advanced Research Projects Agency for Health.

与此同时，韩国政府最近还宣布，它打算开发一个系统，以快速开发和验证非免疫性实体癌的新药靶标，这是韩国卫生高级研究计划署（Korean Advanced Research Projects Agency for Health）举措的一部分。

Besides the government, private national efforts are also pursuing AI-enabled drug discovery in South Korea. For one, AI company Standigm has partnered with Institut Pasteur Korea to develop new anti-tuberculosis drug candidates. It tied up with Merck Korea as well. Meanwhile, Pharma giant Daewoong Pharmaceutical unveiled its AI-driven drug development system, powered by an 800 million-compound database..

除了政府之外，私人国家努力也在韩国寻求人工智能药物发现。首先，AI公司Standigm与韩国巴斯德研究所合作开发新的抗结核候选药物。它还与默克（Merck Korea）合作。与此同时，制药巨头大宇制药（Daewoong Pharmaceutical）推出了其人工智能驱动的药物开发系统，该系统由8亿个化合物数据库提供支持。。

Tags: J INTS BIO, South Korea, Yonsei University, KAIST, AI, AI drug discovery, AI drug development

标签：J INTS BIO，韩国，延世大学，KAIST，AI，AI药物发现，AI药物开发

More regional news

更多地区新闻

Neurophet locks in on China and more briefsBy Adam AngNovember 10, 2024

Vietnam OKs Korean predictive sepsis AI By Adam AngNovember 04, 2024

越南OKs韩国预测性败血症AI作者Adam Ang2024年11月4日

ChatGPT's language bias poses risk in public health response: studyBy Adam AngOctober 29, 2024

ChatGPT的语言偏见对公共卫生反应构成风险：Adam AngOctober 292024的研究